Its rating is now a buy with a new discounted cashflow-derived target price of RM4 from RM3.30, which is at a 2% yield.
PETALING JAYA: Duopharma Biotech Bhd
has been upgraded to a buy from a sell by RHB Research, given the increased clarity on its chances to participate in vaccine rolloutss in the country.
The research house also noted that its human insulin contract had also been extended.
Already a subscriber? Log in.
Subscribe now for a chance to win your dream holiday!
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
